Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives

References

• InstituteNCSEER Cancer Statistics Factsheets: Thyroid CancerNational Cancer InstituteBethesda, MD Available from: http://seer.cancer.gov/statfacts/html/thyro.htmlAccessed October 10, 2015
   Google Scholar
• PellegritiGFrascaFRegalbutoCSquatritoSVigneriRWorldwide increasing incidence of thyroid cancer: update on epidemiology and risk factorsJ Cancer Epidemiol2013201396521223737785
   PubMedGoogle Scholar
• American Thyroid Association Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid CancerCooperDSDohertyGMRevised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancerThyroid200919111167121419860577
   PubMed Web of Science ®Google Scholar
• BrennerHLong-term survival rates of cancer patients achieved by the end of the 20th century: a period analysisLancet200236093401131113512387961
   PubMed Web of Science ®Google Scholar
• DuranteCHaddyNBaudinELong-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapyJ Clin Endocrinol Metab20069182892289916684830
   PubMed Web of Science ®Google Scholar
• CarterSKBlumRHNew chemotherapeutic agents – bleomycin and adriamycinCA Cancer J Clin19742463223314140753
   PubMed Web of Science ®Google Scholar
• GottliebJAHillCSJrChemotherapy of thyroid cancer with adriamycin. Experience with 30 patientsN Engl J Med197429041931974808917
   PubMed Web of Science ®Google Scholar
• ShimaokaKSchoenfeldDADeWysWDCreechRHDeContiRA randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinomaCancer1985569215521603902203
   PubMed Web of Science ®Google Scholar
• NairALemerySJYangJFDA approval summary: lenvatinib for progressive, radio-iodine-refractory differentiated thyroid cancerClin Cancer Res201521235205520826324740
   PubMed Web of Science ®Google Scholar
• BaselgaJCortesJKimSBPertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerN Engl J Med2012366210911922149875
   PubMed Web of Science ®Google Scholar
• LarkinJDel VecchioMAsciertoPAVemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety studyLancet Oncol201415443644424582505
   PubMed Web of Science ®Google Scholar
• BlankeCDRankinCDemetriGDPhase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033J Clin Oncol200826462663218235122
   PubMed Web of Science ®Google Scholar
• MaemondoMInoueAKobayashiKGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med2010362252380238820573926
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NetworkIntegrated genomic characterization of papillary thyroid carcinomaCell2014159367669025417114
   PubMed Web of Science ®Google Scholar
• FerraraNGerberHPLeCouterJThe biology of VEGF and its receptorsNat Med20039666967612778165
   PubMed Web of Science ®Google Scholar
• YuXMLoCYLamAKLeungPLukJMSerum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinomaAnn Surg2008247348348918376194
   PubMed Web of Science ®Google Scholar
• SalajeghehASmithRAKasemKSingle nucleotide polymorphisms and mRNA expression of VEGF-A in papillary thyroid carcinoma: potential markers for aggressive phenotypesEur J Surg Oncol2011371939921093207
   PubMed Web of Science ®Google Scholar
• BaroneMVSepeLMelilloRMRET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein RhoOncogene200120486973698211704822
   PubMed Web of Science ®Google Scholar
• St BernardRZhengLLiuWWinerDAsaSLEzzatSFibroblast growth factor receptors as molecular targets in thyroid carcinomaEndocrinology200514631145115315564323
   PubMed Web of Science ®Google Scholar
• Ricarte-FilhoJCRyderMChitaleDAMutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1Cancer Res200969114885489319487299
   PubMed Web of Science ®Google Scholar
• KomminothPThe RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implicationsVirchows Arch19974311199247627
   PubMed Web of Science ®Google Scholar
• ChenKTLinJDLiouMJWengHFChangCAChanECAn aberrant autocrine activation of the platelet-derived growth factor alpha-receptor in follicular and papillary thyroid carcinoma cell linesCancer Lett2006231219220516126335
   PubMed Web of Science ®Google Scholar
• ZhangJWangPDykstraMPlatelet-derived growth factor receptor-alpha promotes lymphatic metastases in papillary thyroid cancerJ Pathol2012228224125022744707
   PubMed Web of Science ®Google Scholar
• RiveraMRicarte-FilhoJKnaufJMolecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patternsMod Pathol20102391191120020526288
   PubMed Web of Science ®Google Scholar
• WilhelmSMCarterCTangLBAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisCancer Res200464197099710915466206
   PubMed Web of Science ®Google Scholar
• CarlomagnoFAnagantiSGuidaTBAY 43-9006 inhibition of oncogenic RET mutantsJ Natl Cancer Inst200698532633416507829
   PubMed Web of Science ®Google Scholar
• BroseMSNuttingCMJarzabBSorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialLancet2014384994031932824768112
   PubMed Web of Science ®Google Scholar
• FerrariSMPolittiUSpisniRSorafenib in the treatment of thyroid cancerExpert Rev Anticancer Ther201515886387426152651
   PubMed Web of Science ®Google Scholar
• ZhangLZhouQMaLWuZWangYMeta-analysis of dermatological toxicities associated with sorafenibClin Exp Dermatol201136434435021507035
   PubMed Web of Science ®Google Scholar
• RenZZhuKKangHRandomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinomaJ Clin Oncol201533889490025667293
   PubMed Web of Science ®Google Scholar
• SantoniMContiADe GiorgiURisk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trialsInt J Cancer2014135476377324127298
   PubMed Web of Science ®Google Scholar
• MatsuiJFunahashiYUenakaTWatanabeTTsuruokaAAsadaMMulti-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinaseClin Cancer Res200814175459546518765537
   PubMed Web of Science ®Google Scholar
• MatsuiJYamamotoYFunahashiYE7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibitionInt J Cancer2008122366467117943726
   PubMed Web of Science ®Google Scholar
• OkamotoKKodamaKTakaseKAntitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor modelsCancer Lett201334019710323856031
   PubMed Web of Science ®Google Scholar
• YamamotoYMatsuiJMatsushimaTLenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverageVasc Cell201461825197551
   PubMedGoogle Scholar
• TohyamaOMatsuiJKodamaKAntitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer modelsJ Thyroid Res2014201463874725295214
   PubMedGoogle Scholar
• GlenHMasonSPatelHMacleodKBruntonVGE7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasionBMC Cancer20111130921781317
   PubMed Web of Science ®Google Scholar
• GivolDYayonAComplexity of FGF receptors: genetic basis for structural diversity and functional specificityFASEB J1992615336233691464370
   PubMed Web of Science ®Google Scholar
• ShinguKFujimoriMItoKExpression of fibroblast growth factor-2 and fibroblast growth factor receptor-1 in thyroid diseases: difference between neoplasms and hyperplastic lesionsEndocr J199845135439625444
   PubMed Web of Science ®Google Scholar
• OnoseHEmotoNSugiharaHShimizuKWakabayashiIOverexpression of fibroblast growth factor receptor 3 in a human thyroid carcinoma cell line results in overgrowth of the confluent culturesEur J Endocrinol1999140216917310069663
   PubMed Web of Science ®Google Scholar
• KoziczakMHolbroTHynesNEBlocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclinsOncogene200423203501350815116089
   PubMed Web of Science ®Google Scholar
• KondoTZhengLLiuWKurebayashiJAsaSLEzzatSEpigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progressionCancer Res200767115461547017545628
   PubMed Web of Science ®Google Scholar
• YamadaKYamamotoNYamadaYPhase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumorsClin Cancer Res20111782528253721372218
   PubMed Web of Science ®Google Scholar
• BossDSGlenHBeijnenJHA phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumoursBr J Cancer2012106101598160422516948
   PubMed Web of Science ®Google Scholar
• CabanillasMESchlumbergerMJarzabBA phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessmentCancer2015121162749275625913680
   PubMed Web of Science ®Google Scholar
• SchlumbergerMJarzabBCabanillasMEA phase 2 trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC)Clin Cancer Res2016221445326311725
   PubMed Web of Science ®Google Scholar
• SchlumbergerMTaharaMWirthLJLenvatinib versus placebo in radioiodine-refractory thyroid cancerN Engl J Med2015372762163025671254
   PubMed Web of Science ®Google Scholar
• Kate NewboldRETaylorMHKrzyzanowskaMKEfficacy and safety of lenvatinib for the treatment of patients with131I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy. ASCO Annual Meeting 2015J Cli Oncol201533Suppl Abstract 6013
   Google Scholar
• ShumakerRCZhouMRenMEffect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteersCancer Chemother Pharmacol20147361109111724658627
   PubMed Web of Science ®Google Scholar
• GuoMSSWirthLOverall survival gain with lenvatinib vs. placebo in radioactive iodine refractory differentiated thyroid cancer (RR-DTC): an updated analysis18th ECCO – 40th ESMO European Cancer Congress, Proffered Paper SessionSeptember, 2015Vienna, Austria
   Google Scholar
• ShahRRMorganrothJUpdate on cardiovascular safety of tyrosine kinase inhibitors: with a special focus on QT interval, left ventricular dysfunction and overall risk/benefitDrug Saf201538869371026008987
   PubMed Web of Science ®Google Scholar
• Lenvima [package insert]Eisai Inc. under license from Eisai R&D Management Co., Ltd
   Google Scholar
• BlevinsDPDaduRHuMAerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancerThyroid201424591892224635127
   PubMed Web of Science ®Google Scholar
• BasilleDAndrejakMBentayebHBronchial fistula associated with sunitinib in a patient previously treated with radiation therapyAnn Pharmacother201044238338620118139
   PubMed Web of Science ®Google Scholar
• GoreECurreyAChoongNTracheoesophageal fistula associated with bevacizumab 21 months after completion of radiation therapyJ Thorac Oncol20094121590159120009916
   PubMed Web of Science ®Google Scholar
• SchutzFAJeYRichardsCJChoueiriTKMeta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitorsJ Clin Oncol201230887187722312105
   PubMed Web of Science ®Google Scholar
• KimuraETNikiforovaMNZhuZKnaufJANikiforovYEFaginJAHigh prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinomaCancer Res20036371454145712670889
   PubMed Web of Science ®Google Scholar
• HouPLiuDXingMFunctional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancerCell Cycle20076337737917297294
   PubMed Web of Science ®Google Scholar
• XingMLiuRLiuXBRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrenceJ Clin Oncol201432252718272625024077
   PubMed Web of Science ®Google Scholar
• LiuZHouPJiMHighly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancersJ Clin Endocrinol Metab20089383106311618492751
   PubMed Web of Science ®Google Scholar
• AbubakerJJehanZBaviPClinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern populationJ Clin Endocrinol Metab200893261161818000091
   PubMed Web of Science ®Google Scholar
• SchlumbergerMMassicotteMHNascimentoCLChougnetCBaudinELeboulleuxSKinase inhibitors for advanced medullary thyroid carcinomaClinics (Sao Paulo)201267suppl 112512922584717
   PubMedGoogle Scholar
• BunoneGVigneriPMarianiLExpression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological featuresAm J Pathol199915561967197610595926
   PubMed Web of Science ®Google Scholar
• CappCWajnerSMSiqueiraDRBrasilBAMeurerLMaiaALIncreased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinomaThyroid201020886387120615131
   PubMed Web of Science ®Google Scholar
• Rodriguez-AntonaCPallaresJMontero-CondeCOverexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasisEndocr Relat Cancer201017171619776290
   PubMed Web of Science ®Google Scholar
• Makoto TaharaMSRossellaEMouhammedAHPharmacodynamic biomarkers of outcomes in the phase III study of lenvatinib in 131I-refractory differentiated thyroid cancer (SELECT). ASCO Annual Meeting 2015J Clin Oncol201533Suppl Abstract 6014
   Google Scholar
• MarciaSBroseMSMakotoTEffect of age and lenvatinib treatment on overall survival for patients with 131I-refractory differentiated thyroid cancer in SELECT. ASCO Annual Meeting 2015J Clin Oncol201533Suppl Abstract 6048
   Google Scholar
• HaugenBRMAlexanderEKBibleKC2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid CancerThyroid2015
   Web of Science ®Google Scholar
• GuidelinesNNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) Version 22015 Available from: http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdfAccessed December 20, 2015
   Google Scholar
• TouatMIleanaEPostel-VinaySAndreFSoriaJCTargeting FGFR signaling in cancerClin Cancer Res201521122684269426078430
   PubMed Web of Science ®Google Scholar
• SchlumbergerBJEliseiRlSienaSPhase III randomized, double-blinded, placebo-controlled trial of sorafenib in locally advanced or metastatic patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DCT)-Exploratory analyses of patient-reported outcomes83rd American Thyroid Association Meeting2013
   Google Scholar
• DaduRDevineCHernandezMRole of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenibJ Clin Endocrinol Metab20149962086209424628550
   PubMed Web of Science ®Google Scholar
• ClinicalTrial.gov [database on the Internet]Dabrafenib with or without trametinib in treating patients with recurrent thyroid cancerAccessed October 3, 2015
   Google Scholar
• RucoLPRanalliTMarzulloAExpression of Met protein in thyroid tumoursJ Pathol199618032662708958803
   PubMed Web of Science ®Google Scholar
• KooBSKimJMSeoSTUpregulation of HGF and c-MET is associated with subclinical central lymph node metastasis in papillary thyroid microcarcinomaAnn Surg Oncol20142172310231724562934
   PubMed Web of Science ®Google Scholar
• ScarpinoSStoppacciaroAColarossiCHepatocyte growth factor (HGF) stimulates tumour invasiveness in papillary carcinoma of the thyroidJ Pathol1999189457057510629560
   PubMed Web of Science ®Google Scholar
• ScarpinoSD’AlenaFCDi NapoliABallariniFPratMRucoLPPapillary carcinoma of the thyroid: evidence for a role for hepatocyte growth factor (HGF) in promoting tumour angiogenesisJ Pathol2003199224325012533838
   PubMed Web of Science ®Google Scholar
• MineoRCostantinoAFrascaFActivation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levelsEndocrinology200414594355436515192042
   PubMed Web of Science ®Google Scholar
• ChattopadhyayCEl-NaggarAKWilliamsMDClaymanGLSmall molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinomaHead Neck2008308991100018327775
   PubMed Web of Science ®Google Scholar
• NakagawaTMatsushimaTKawanoSLenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitorCancer Sci2014105672373024689876
   PubMed Web of Science ®Google Scholar
• ClinicalTrial.gov [database on the Internet]E7050 in combination with E7080 in subjects with advanced solid tumors (dose escalation) and in subjects with recurrent glioblastoma or unresectable stage III or stage IV melanoma after prior systemic therapy (expansion cohort and phase 2)Accessed October 3, 2015
   Google Scholar
• DienstmannRBranaIRodonJTaberneroJToxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugsOncologist201116121729174022135123
   PubMed Web of Science ®Google Scholar
• RavaudASchmidingerMClinical biomarkers of response in advanced renal cell carcinomaAnn Oncol201324122935294223925998
   PubMed Web of Science ®Google Scholar
• KoyamaNSaitoKNishiokaYPharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinibBMC Cancer20141453025047123
   PubMed Web of Science ®Google Scholar
• SimSHKeamBKimDWThe gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancerJ Cancer Res Clin Oncol2014140122135214225005787
   PubMed Web of Science ®Google Scholar
• YeoWLRielyGJYeapBYErlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutationsJ Thorac Oncol2010571048105320512075
   PubMed Web of Science ®Google Scholar
• FaberEDivokaMSkoumalovaIA lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatmentLeuk Lymphoma20165721626059059
   PubMed Web of Science ®Google Scholar
• ClinicalTrial.gov [database on the Internet]An expanded access program with lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancerAccessed October 3, 2015
   Google Scholar
• BurtnessBAnadkatMBastiSNCCN Task Force Report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancerJ Natl Compr Canc Netw20097suppl 1S5S2119470276
   PubMed Web of Science ®Google Scholar
• BroseMSFrenetteCTKeefeSMSteinSMManagement of sorafenib-related adverse events: a clinician’s perspectiveSemin Oncol201441suppl 2S1S1624576654
   PubMedGoogle Scholar
• CarhillAACabanillasMEJimenezCThe non-investigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoringJ Clin Endocrinol Metab2013981314223185034
   PubMed Web of Science ®Google Scholar
• CarrLLMankoffDAGoulartBHPhase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlationClin Cancer Res201016215260526820847059
   PubMed Web of Science ®Google Scholar
• CohenEERosenLSVokesEEAxitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II studyJ Clin Oncol200826294708471318541897
   PubMed Web of Science ®Google Scholar
• BibleKCSumanVJMolinaJREfficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium studyLancet Oncol2010111096297220851682
   PubMed Web of Science ®Google Scholar
• ShermanSIWirthLJDrozJPMotesanib diphosphate in progressive differentiated thyroid cancerN Engl J Med20083591314218596272
   PubMed Web of Science ®Google Scholar
• CabanillasMEBroseMSHollandJFergusonKCShermanSIA phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancerThyroid201424101508151425102375
   PubMed Web of Science ®Google Scholar
• LeboulleuxSBastholtLKrauseTVandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trialLancet Oncol201213989790522898678
   PubMed Web of Science ®Google Scholar
• BroseMS CMCohenEEWWirthLAn open-label, multi-center phase 2 study of the BRAF inhibitor vemurafenib in patients with metastatic or unresectable papillary thyroid cancer positive for the BRAF V600 mutation and resistant to radioactive iodineEur J Cancer201349E177119
   PubMed Web of Science ®Google Scholar
• FalchookGSMillwardMHongDBRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancerThyroid2015251717725285888
   PubMed Web of Science ®Google Scholar
• HoALGrewalRKLeboeufRSelumetinib-enhanced radioiodine uptake in advanced thyroid cancerN Engl J Med2013368762363223406027
   PubMed Web of Science ®Google Scholar
• ChowLQEckhardtSGSunitinib: from rational design to clinical efficacyJ Clin Oncol200725788489617327610
   PubMed Web of Science ®Google Scholar
• Hu-LoweDHallinMFeeleyRCharacterization of potency and activity of the VEGF/PDGF receptor tyrosine kinase inhibitor AG013736Am Assoc Cancer Ress2002435357
   Google Scholar
• KumarRKnickVBRudolphSKPharmacokinetic- pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activityMol Cancer Ther2007672012202117620431
   PubMed Web of Science ®Google Scholar
• HurwitzHIDowlatiASainiSPhase I trial of pazopanib in patients with advanced cancerClin Cancer Res200915124220422719509175
   PubMed Web of Science ®Google Scholar
• PolverinoACoxonAStarnesCAMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenograftsCancer Res200666178715872116951187
   PubMed Web of Science ®Google Scholar
• YakesFMChenJTanJCabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growthMol Cancer Ther201110122298230821926191
   PubMed Web of Science ®Google Scholar
• FallahiPFerrariSMDi BariFCabozantinib in thyroid cancerRecent Pat Anticancer Drug Discov201510325926926152149
   PubMed Web of Science ®Google Scholar
• WedgeSROgilvieDJDukesMZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administrationCancer Res200262164645465512183421
   PubMed Web of Science ®Google Scholar
• CarlomagnoFVitaglianoDGuidaTZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinasesCancer Res200262247284729012499271
   PubMed Web of Science ®Google Scholar
• SalernoPDe FalcoVTamburrinoACytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cellsJ Clin Endocrinol Metab201095145045519880792
   PubMed Web of Science ®Google Scholar
• BanerjiUCamidgeDRVerheulHMThe first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancerClin Cancer Res20101651613162320179232
   PubMed Web of Science ®Google Scholar
• BollagGHirthPTsaiJClinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature2010467731559659920823850
   PubMed Web of Science ®Google Scholar